ClinicalTrials.gg
RecruitingNCT05363748Updated Nov 18, 2023

Renal Artery Fibromuscular Dysplasia Registry

An observational study in Renal Artery Fibromuscular Dysplasia, sponsored by Shanghai Jiao Tong University School of Medicine. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2023-11-18.

Sponsored by Shanghai Jiao Tong University School of Medicine · Observational

How we know

From the registry’s dates

  • Started Oct 2021; still recruiting 5 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Hypertension by Shanghai Jiao Tong University School of Medicine — 6 open to participants now, 7 under way, none of them phase 3. Hypertension · Shanghai Jiao Tong University School of Medicine.

Started
2021
with 2 others
Observational
2 of 15
2 open now
Registered
9th of 15
by date

Among the 15 studies in Hypertension by Shanghai Jiao Tong University School of Medicine, this one is one of 3 that started in 2021, is one of 2 observational ones, and was the 9th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

6 of the 15 studies in Hypertension by Shanghai Jiao Tong University School of Medicine are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Hypertension by Shanghai Jiao Tong University School of Medicine, or all of them as a file.
02

Study summary

  1. Study name: A Prospective Study of the Renal artery fibromuscular dysplasia Registry in China
  2. Rationale: Fibromuscular dysplasia (FMD) is an idiopathic systemic noninflammatory arterial disease resulting in narrowing of medium-sized arteries. Renal arteries are most commonly involved vessels, although it can also affect arteries in other vascular territories. Renal artery FMD is the second frequent cause of renovascular hypertension , especially in adolescents. The pathogenesis of FMD is still not understood. There were little Asians in the United States and the European/International FMD registry.
  3. Objective: 1) To describe the characteristics of renal artery FMD; 2) To identify environmental/ hormonal factors and exposures (for example smoking) associated with the onset and progression of renal artery FMD; 3)To identify baseline characteristics of the disease associated with an increased risk of complications such as dissections, aneurysms, stroke or myocardial infarction; 4) To provide evidence-based algorithms for the management and follow-up of patients with renal artery FMD; 5) To establish a comprehensive imaging resource including a wide range of presentations of renal artery FMD.
  4. Study design: Prospective, multi-center, observational study.
  5. Study population: renal artery fibromuscular dysplasia
  6. Data Collections: 1) Data on demographic characteristics, clinical characteristics, blood routine, biochemical and plasmic electrolytes and vascular imaging were collected using a questionnaire; 2) The diagnosis of renal artery FMD was based on the identification of focal or multifocal FMD lesions in at least one arterial bed by computed tomography angiography, magnetic resonance angiography and/or digital subtraction angiographies; 3) For the patients with renal artery FMD, screening was performed to assess most arteries and multivessel FMD would be collected; 4) All patients would be followed up.
  7. Treatment: Standardized diagnosis and treatment procedure as recommended in the International Consensus on the diagnosis and management of fibromuscular dysplasia.
  8. Follow up: 3, 6, 12 months after diagnosis and every year after enrolled.
  9. Sample size estimation: About 5 hundred.
  10. Timeline: Start of subjects' enrollment: Jan 2021; End of subjects enrollment: December 2026; End of study: December 2036.
  11. Organization: The Centre for Epidemiological Studies and Clinical Trials, Ruijin Hospital, Shanghai, China.
Read the detailed description
  1. Study name: A Prospective Study of the Renal artery fibromuscular dysplasia Registry in China
  2. Rationale: Fibromuscular dysplasia (FMD) is an idiopathic systemic noninflammatory arterial disease resulting in narrowing of medium-sized arteries and causes stenosis, aneurysm, occlusion, or dissection. Renal arteries are most commonly involved vessels, although it can also affect arteries in other vascular territories. Renal artery FMD is the second frequent cause of renovascular hypertension (RVH), especially in adolescents. FMD often affects two or more arterial beds (prevalence of multivessel FMD: 57 to 66%). Despite traditional views on the role of female hormones, mechanical factors and, more recently, smoking, the pathophysiology of FMD is still not well understood. There were little Asians in the United States and the European/International FMD registry.
  3. Objective: 1) To describe the characteristics of renal artery FMD in men and women, older and younger patients and according to different arterial manifestations, ethnic origin in order to individualize management and prevent complications; 2) To identify environmental/ hormonal factors and exposures (for example smoking) associated with the onset and progression of renal artery FMD;3)To identify baseline characteristics of the disease associated with an increased risk of complications such as dissections, aneurysms, stroke or myocardial infarction; 4) To provide evidence-based algorithms for the optimal management and follow-up of patients with renal artery FMD; 5) To establish a comprehensive imaging resource including a wide range of presentations of renal artery FMD, which may be used to improve knowledge and raise awareness in the medical community.
  4. Study design: Prospective, multi-center, observational study.
  5. Study population: patients with renal artery fibromuscular dysplasia who signed the informed consent will be eligible. The following patients are eligible for inclusion: 1) Patients with established renal artery FMD, at least one string-of-beads (multifocal FMD) or focal stenosis (focal FMD). 2) Patients with so-called "atypical FMD" or "FMD-like presentation", i.e. patients presenting with at least one dissection or 2 aneurysms \< 60-year-old, in the absence string-of-beads, focal stenosis or evidence of inherited arteriopathy. 3) Children with renal artery FMD may be also included, provided they meet the inclusion criteria and there is no evidence of underlying syndromes such as Williams syndrome, Alagille syndrome or type 1 Neurofibromatosis.
  6. Data Collections: 1) Data on demographic characteristics (age, gender, height, and ethnicity), clinical characteristics [seated office systolic and diastolic blood pressure (BP), smoking, family history on hypertension or FMD, concomitant diseases, current medications, age at diagnosis of renal artery FMD, angiographic subtype of renal artery FMD, symptoms of renal artery FMD at diagnosis and associated atheroma lesions], blood routine, biochemical and plasmic electrolytes and vascular imaging (arterial beds explored, imaging modality, type, and site of lesions for each vascular bed) were collected using a questionnaire; 2) The diagnosis of renal artery FMD was based on the identification of focal or multifocal FMD lesions in at least one arterial bed by computed tomography angiography (CTA), magnetic resonance angiography(MRA) and/or digital subtraction angiographies (DSA), as recommended in the first international FMD Consensus; 3) For the patients with renal artery FMD, screening was performed to assess all arteries (for example: cerebrovascular, mesenteric, aorta, renal, coronary, visceral, upper and lower extremity arteries) and multivessel FMD would be collected. 4) All patients would be followed up and data ( for example: the blood pressure and restenosis) would be evaluated again.
  7. Treatment: Standardized diagnosis and treatment procedure as recommended in the International Consensus on the diagnosis and management of fibromuscular dysplasia.
  8. Follow up: 3, 6, 12 months after diagnosis and every year after enrolled.
  9. Sample size estimation: About 5 hundred.
  10. Timeline: Start of subjects' enrollment: Jan 2021; End of subjects enrollment: December 2026; End of study: December 2036.
  11. Organization: The Centre for Epidemiological Studies and Clinical Trials, Ruijin Hospital, Shanghai, China.
03

Conditions studied

  • Renal Artery Fibromuscular Dysplasia

Browse trials for

Keywords

  • Renal Artery Fibromuscular Dysplasia
  • Hypertension
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients with renal artery fibromuscular dysplasia who signed the informed consent will be eligible. The following patients are eligible for inclusion: 1) Patients with established renal artery FMD, at least one string-of-beads (multifocal FMD) or focal stenosis (focal FMD). 2) Patients with so-called "atypical FMD" or "FMD-like presentation", i.e. patients presenting with at least one dissection or 2 aneurysms \< 60-year-old, in the absence string-of-beads, focal stenosis or evidence of inherited arteriopathy. 3) Children with renal artery FMD may be also included, provided they meet the inclusion criteria and there is no evidence of underlying syndromes such as Williams syndrome, Alagille syndrome or type 1 Neurofibromatosis.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ;
  2. Patients diagnosed with renal artery fibromuscular dysplasia (FMD), i.e. at least one string-of-beads (multifocal FMD) or focal stenosis (focal FMD). The diagnosis needs to be confirmed by at least one of the following imaging modalities: CT-angiography, MR-angiography or catheter-based angiography;
  3. Patients with so-called "atypical renal artery FMD" or "renal artery FMD-like presentation", i.e. patients presenting with at least one dissection or 2 aneurysms \< 60-year-old, in the absence string-of-beads, focal stenosis or evidence of inherited arteriopathy;
  4. Patients with established renal artery FMD younger than 18 years, without evidence of underlying syndromes such as Williams syndrome, Alagille syndrome or type 1 Neurofibromatosis;

Exclusion criteria

Exclusion Criteria:

  1. Not eligible for inclusion or in situations considered unqualified for the study by the investigator;
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Observation group

    sequential

06

What researchers measure

Primary outcomes

  1. The percentage of focal or multifocal FMD

    The percentage of focal or multifocal subtype in the renal artery FMD in China

    Time frame: 1 day

  2. The percentage of multivessel FMD in the renal artery FMD

    The percentage of multivessel FMD in the renal artery FMD in China

    Time frame: 1 week

  3. The change of blood pressure

    Comparison of blood pressure between baseline and 3/6/12 months (every year) after percutaneous transluminal angioplasty.

    Time frame: 10 years

  4. The rate of restenosis of renal artery FMD

    The rate of restenosis of renal artery FMD after percutaneous transluminal angioplasty

    Time frame: 10 years

  5. The rate of incidence of cardiovascular events

    The rate of incidence of cardiovascular events in the renal artery FMD patients, such as cerebral infarction, hypertensive nephropathy, myocardial infarction and so on.

    Time frame: 10 years

07

Study locations

1 of 1 sites recruiting
  • Shanghai Institite of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai 200025, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2021 (actual). Primary completion is estimated for Dec 2026, 62 months after the start.

Of 348 non-industry observational studies under Hypertension, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 111. This study's planned 62 months is above that.

Counting every sponsor, half of 429 studies reached it within 38 months; a quarter within 17 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2022
First posted
May 6, 2022
StartActual
Oct 1, 2021
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2036
Last update
Nov 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05363748
Responsible party
Ji-Guang Wang (Director of the Shanghai Institute of Hypertension and the Department of Hypertension, Shanghai Jiao Tong University School of Medicine) — Principal investigator
First posted
May 6, 2022
Start date
Oct 1, 2021
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2036 (estimated)
Last update
Nov 18, 2023

Study contacts

Jiguang Wang, MD, PhD
Contact
jiguangw@163.com
+86-21-64370045 ext. 610911
Jiguang Wang, MD, PhD
Contact
iguang_wang_jgw@yahoo.com
+86-21-64370045 ext. 610911
Jiguang Wang, PhD
principal investigator · Shanghai Jiao Tong University School of Medicine Ruijin Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion